Source: Gerd Altmann , no changes made.
Orgenesis Inc. a developer, manufacturer and service provider of advanced cell therapies, recently released financial results and provided a business update for the fiscal year ended November 30, 2018. A variety of deals were made during the year including with the New York Blood Center (NYBC) to collect, process, test, cryopreserve and biobank sampling materials. This included liver biopsies for use as source of autologous insulin producing (AIP) cells.
Founded in 2008, headquartered in Germantown, Maryland, USA, Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and support services. The company has a global contract development and manufacturing organization (CDMO) subsidiary, as well as developing its own cell therapy products for diabetes.
“As an example of our progress, we recently announced a collaboration with MangoGen Pharma Inc., initially focused on the pre-clinical development of insulin producing cells (IPC) using MangoGen’s advanced gene delivery platform. In support of this program, we were awarded a grant from the Canada-Israel Industrial R&D Foundation (CIIRDF) to fund this project. We also announced a licensing and collaboration agreement with BGN Technologies, an affiliate of Ben-Gurion University of the Negev (BGU), to advance the research and development of BGU’s dissolvable carriers for cell culturing, in which we received the exclusive, worldwide rights to make, develop and commercialize technologies utilizing dissolvable carriers for cell culturing. This unique technology has the potential to significantly reduce the cost and complexity of manufacturing for our cell therapy programs.”
“We entered into a collaboration agreement with the New York Blood Center (NYBC), one of the largest independent, community-based blood centers in the world to collect, process, test, cryopreserve and biobank sampling materials, including liver biopsies for use as source of autologous insulin producing (AIP) cells for patients that may be eligible for future clinical trials. We also announced two important agreements with Hemogenyx Pharmaceuticals and its subsidiary, Immugenyx. The first collaboration is focused on the development and commercialization of Hemogenyx’ Human Postnatal Hemogenic Endothelial (Hu-PHEC) technology, a cell replacement product candidate that is designed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient. The second collaboration is focused on the development and commercialization of Immugenyx’ advanced hematopoietic chimeras (AHC), a new type of humanized mouse with a functional human immune system, as an in vivo platform for disease modelling, drug and cell therapy development.”
“Looking ahead, we are advancing a number of additional such agreements that have the potential to significantly enhance our POCare cellular therapy platform, which we look forward to announcing in the coming weeks and months.” – Vered Caplan, CEO of Orgenesis
Sources:
